





























- [101] meningococcal vaccines[J]. Hum Vaccin Immunother, 2020, 1-12. DOI: 10.1080/21645515.2020.1739485.
- [102] Martinón-Torres F, Boisnard F, Thomas S, et al. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP 5-IPV-Hib) [J]. Vaccine, 2017, 35(30): 3764-3772. DOI: 10.1016/j.vaccine.2017.05.043.
- [103] 唐伟,甘霖,黄毅,等.口服轮状病毒减毒活疫苗与麻疹-风疹联合减毒活疫苗联合接种的免疫原性和安全性研究[J].川北医学院学报,2016,31(5):710-712.  
Tang W, Gan L, Huang Y, et al. Study on immunogenicity and safety of oral attenuated rotavirus vaccine and measles-rubella vaccine [J]. J North Sichuan Med College, 2016, 31(5):710-712.
- [104] 黄顺和,唐伟,王娟,等.口服轮状病毒减毒活疫苗与麻疹-风疹-流行性腮腺炎联合减毒活疫苗联合接种的免疫原性和安全性研究[J].预防医学情报杂志,2016,32(5):472-475.  
Huang SH, Tang W, Wang J, et al. Study on immunogenicity and safety of oral attenuated rotavirus live vaccine and measles-rubella-mumps live vaccine [J]. Prev Med J Infor, 2016, 32(5):472-475.
- [105] Goveia MG, Suprun L, Itzler RF, et al. Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses[J]. Pediatr Infect Dis J, 2010, 29(3): 263-5. DOI: 10.1097/INF.0b013e3181be6257
- [106] Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants[J]. Pediatr Infect Dis J, 2007, 26(12): 1099-104. DOI: 10.1097/INF.0b013e31814521cb.
- [107] 季钗.特殊健康状态儿童预防接种专家共识之一——早产儿与预防接种[J].中国实用儿科杂志,2018,33(10):737-738.
- [108] Ji C. One of the consensus of experts on vaccination for children in special health state-premature infants and vaccination [J]. Chin J Appl Pediatrics, 2018, 33(10): 737-738.
- [109] World Health Organization. Training modules for Health Care Workers. Module 4-Rotavirus vaccine administration. [EB/OL]. [2020-11-01]. [https://www.who.int/immunization/diseases/rotavirus/training\\_modules\\_HC\\_workers\\_no\\_age\\_restrictions\\_rotateq/en/](https://www.who.int/immunization/diseases/rotavirus/training_modules_HC_workers_no_age_restrictions_rotateq/en/)
- [110] Marshall GS. 周祖木,译.疫苗手册:临床医生实用指南:第4版[M].北京:北京大学医学出版社. 2014.
- [111] Marshall GS/ Translated by Zhou ZM. Vaccine Manual: Practical Guide for Clinicians: 4th Edition [M]. Beijing: Peking University Medical Press, 2014.
- [112] 耿启彬,赖圣杰,余建兴,等.中国26省(直辖市、自治区)2011-2014年5岁以下儿童腹泻病例轮状病毒流行特征分析[J].疾病监测,2016,31(6):463-470.
- [113] Geng QB, Lai SJ, Yu JX, et al. Epidemiological characteristics of rotavirus in diarrhea cases of children under 5 years old in 26 provinces (municipalities and autonomous regions) of China from 2011 to 2014 [J]. Dis Surveill, 2016, 31(6):463-470.
- [114] Burnett E, Jonesteller CL, Tate JE, et al. Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea[J]. J Infect Dis, 2017, 215(11): 1666-1672. DOI:10.1093/infdis/jix186.
- [115] Peter G, Myers MG, National Vaccine Advisory Committee; National Vaccine Program Office. Intussusception, rotavirus, and oral vaccines: summary of a workshop[J]. Pediatrics, 2002, 110(6): e67. DOI: 10.1542/peds. 110.6. e67.
- [116] Burnett E, Tate JE, Kirkwood CD, et al. Estimated Impact of Rotavirus Vaccine on Hospitalizations and Deaths from Rotavirus Diarrhea among Children <5 in Asia[J]. Expert Rev Vaccines, 2018, 17(5): 453-460. DOI: 10.1080/14760584.2018.1443008.